SUPLEMENTARY MATERIAL

Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of A Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)

Author names: Blanca Hernández-Cruz[1*], José Rosas[2], César Díaz-Torné[3], Joaquín Belzunegui[4], Rosario García-Vicuña[5], José Inciarte-Mundo[6], Ana Pons[2], Ana M Millán[3], Sicylle Jeria-Navarro[3], Jesús A Valero[4], Noelia García-Castañeda[5], Cristina Valero[5], Irene Llorente[5], Alberto Calvo[5], Silvia Díaz-Cerezo[7], Mercedes Núñez[7].

Affiliations:

1. Rheumatology Department. University Hospital Virgen Macarena. Calle Dr. Fedriani, 3, 41009 Seville, Spain.
2. Rheumatology Department. Marina Baixa Hospital. Av. Alcalde En Jaume Botella Mayor, 7, 03570 Villajoyosa, Alicante, Spain.
3. Arthritis Unit, Rheumatology and Autoimmune Diseases Department, Santa Creu i Sant Pau Hospital. Carrer de Sant Quintí, 89, 08041 Barcelona, Spain.
4. Rheumatology Department. Donostia University Hospital. Begiristain Doktorea Pasealekua, 20014 Guipúzcoa, Spain.
5. Rheumatology Department. University Hospital La Princesa, IIS-IP. Calle de Diego de León, 62, 28006 Madrid, Spain.
6. Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. C. de Villarroel, 170, 08036 Barcelona, Spain.
7. Medical Department. Lilly Spain. Av de la Industria 30, 28108 Alcobendas, Madrid, Spain.

Corresponding Author:

Name: Blanca Hernández-Cruz

Address: Rheumatology Department. Universitary Hospital Virgen Macarena. Calle Dr. Fedriani, 3, 41009 Seville, Spain

Phone: +34 600162280

E-mail: blancae.hernandez.sspa@juntadeandalucia.es; blancahcruz@gmail.com

Table 1S. Baseline patient sociodemographic and clinical characteristics of those patients who discontinued baricitinib treatment due to lack of efficacy.

Variable	**Value**
Total population, n (%)	48 (100)
Age (years)/Mean (SD)	61.3 (12.8)
BMI (Kg/m^2): n/Mean (SD)	26/ 27.5 (6.6)
Time since RA diagnosis (years): n / Mean (SD)	46 / 14.2 (11.2)
Time since RA diagnosis to start of baricitinib treatment (years): n / Mean (SD)	46 / 13.2 (10.8)
Charlson Comorbidity Index: n / Mean (SD)	48 / 2.6 (2.0)
TJC (0-28): n / Mean (SD)	47 / 7.2 (5.6)
SJC (0-28): n/ Mean (SD)	47 / 4.5 (3.5)
CRP (mg/L): n / Mean (SD)	46 / 8.9 (17.0)
ESR (mm/hr): n / Mean (SD)	42 / 30.7 (26.8)
Gender	n (%)
Male	6 (12.5)
Female	42 (87.5)
BMI (categorized)	n (%)
Normal weight (18.5<=BMI<25)	10 (38.5)
Pre-obesity (25<=BMI<=30)	6 (23.1)
Obesity class I (30.0 < BMI < 35)	7 (26.9)
Obesity class II (35>BMI<=40)	2 (7.7)
Obesity class III (BMI>40)	1 (3.8)
N missings	22
Smoking status	n (%)
Current smoker	6 (12.5)
Ex-smoker (>6 months without smoking)	9 (18.8)
Non-smoker	19 (39.6)
Unknown	14 (29.2)
Positive RF (Rheumatoid factor), n (%)	33 (68.8)
Positive ACPA (Anti-citrullinated protein antibodies), n (%)	36 (75.0)
Bone erosions, n (%)	27 (56.3)
Type of extra-articular manifestations (multiresponse), n (%)	
Rheumatoid nodules	6 (12.5)
Sjögren syndrome	4 (8.3)
Interstitial pneumonitis	4 (8.3)
Atlantoaxial subluxation (AAS)	1 (2.1)
Pleuritis	1 (2.1)
Pneumological complications	1 (2.1)
Rheumatoid vasculitis	1 (2.1)
Felty´s syndrome	0 (0.0)
Other manifestations (pericarditis, amyloidosis, Raynaud´s syndrome)	6 (12.5)

Variable	Value
DAS28-ESR Categorizations, n (%)	25 (100.0)
Remission: DAS28<2.6	2 (8.0)
Low activity: 2.6<=DAS28<3.2	1 (4.0)
Moderate Activity: 3.2<=DAS28<5.1	15 (60.0)
High Activity: DAS28>=5.1	7 (28.0)
SDAI Categorizations, n (%)	35 (100.0)
Remission: 0.0<=SDAI<=3.3	0 (0.0)
Low activity: 3.3<SDAI<=11.0	1 (2.9)
Moderate Activity: 11.0<SDAI<=26.0	21 (60.0)
High Activity: 26.0<SDAI<=86.0	13 (37.1)
CDAI Categorizations, n (%)	35 (100)
Remission: 0.0<=CDAI<=3.3	0 (0.0)
Low activity: 3.3<CDAI<=11.0	1 (2.9%)
Moderate Activity: 11.0<CDAI<=26.0	22 (62.9%)
High Activity: 26.0<CDAI<=86.0	12 (34.3%)
Patient’s pain assessment, n	41
Mean (SD)	7.1 (1.5)
Median (P25; P75)	7.0 (6.0; 8.0)

Table 2S. Baseline patient sociodemographic and clinical characteristics according to treatment receive (baricitinib as monotherapy and baricitinib + csDMARD)

Variable	**Monotherapy**	**Baricitinib + csDMARD**
Total population, n (%)	79 (100)	103 (100)
Age (years)/Mean (SD)	63.9 (12.7)	60.83 (11.80)
BMI (Kg/m^2): n/Mean (SD)	31/ 26.8 (4.7)	71/ 26.7 (5.3)
Time since RA diagnosis (years): n / Mean (SD)	74 / 15.6 (12.3)	103 / 13.9 (9.6)
Time since RA diagnosis to start of baricitinib treatment (years): n / Mean (SD)	74 / 14.2 (12.2)	103 / 12.5 (9.6)
Charlson Comorbidity Index: n / Mean (SD)	79 / 2.9 (2.4)	103 / 2.1 (1.5)
TJC (0-28): n / Mean (SD)	78 / 5.7 (4.5)	99 / 7.5 (6.6)
SJC (0-28): n/ Mean (SD)	78 / 4.5 (3.4)	99 / 4.4 (4.0)
CRP (mg/L): n / Mean (SD)	74 / 12.9 (20.4)	102 / 5.4 (10.3)
ESR (mm/hr): n / Mean (SD)	71 / 30.6 (25.2)	100 / 29.1 (23.3)
Gender	n (%)	n (%)
Male	10 (12.7)	20 (19.4)
Female	69 (87.3)	83 (80.6)
Work status	n (%)	n (%)
Employed	16 (20.3)	26 (25.2)
Unemployed	9 (11.4)	9 (8.7)
Retired	27 (34.2)	32 (31.1)
Sick leave	5 (6.3)	7 (6.8)
Unknown	22 (27.8)	29 (28.2)
BMI (categorized)	n (%)	n (%)
Underweight (BMI<18.35)	1 (3.2)	0 (0.0)
Normal weight (18.5<=BMI<25)	11 (35.5)	29 (40.8)
Pre-obesity (25<=BMI<=30)	10 (32.3)	24 (33.8)
Obesity class I (30.0 < BMI < 35)	8 (25.8)	12 (16.9)
Obesity class II (35>BMI<=40)	1 (3.2)	4 (5.6)
N missings	48	32
Smoking status	n (%)	n (%)
Current smoker	9 (11.4)	18 (17.5)
Ex-smoker (>6 months without smoking)	13 (16.5)	18 (17.5)
Non-smoker	37 (46.8)	50 (48.5)
Unknown	20 (25.3)	17 (16.5)
Positive RF (Rheumatoid factor), n (%)	60 (75.9)	84 (81.6)
Positive ACPA (Anti-citrullinated protein antibodies), n (%)	63 (79.7)	83 (80.6)
Bone erosions, n (%)	49 (62.0)	69 (67.0)
Type of extra-articular manifestations (multiresponse), n (%)		
Rheumatoid nodules	16 (20.3)	18 (17.5)
Sjögren syndrome	10 (12.7)	7 (6.8)
Interstitial pneumonitis	9 (11.4)	5 (4.9)

Variable	Monotherapy	Baricitinib + csDMARD
Atlantoaxial subluxation (AAS)	2 (2.5)	4 (3.9)
Pleuritis	3 (3.8)	3 (2.9)
Pneumological complications	2 (2.5)	4 (3.9)
Rheumatoid vasculitis	1 (1.3)	2 (1.9)
Felty´s syndrome	1 (1.3)	1 (1.0)
Other manifestations (pericarditis, amyloidosis, Raynaud´s syndrome)	4 (5.2)	1 (1.0)
DAS28-ESR Categorizations, n (%)	35 (100.0)	66 (100.0)
Remission: DAS28<2.6	4 (11.4)	2 (3.0)
Low activity: 2.6<=DAS28<3.2	4 (11.4)	5 (7.6)
Moderate Activity: 3.2<=DAS28<5.1	21 (60.0)	43 (65.2)
High Activity: DAS28>=5.1	6 (17.1)	16 (24.2)
SDAI Categorizations, n (%)	59 (100.0)	76 (100.0)
Remission: 0.0<=SDAI<=3.3	0 (0.0)	0 (0.0)
Low activity: 3.3<SDAI<=11.0	6 (10.2)	4 (5.1)
Moderate Activity: 11.0<SDAI<=26.0	33 (55.0)	40 (50.6)
High Activity: 26.0<SDAI<=86.0	20 (33.3)	32 (42.1)
CDAI Categorizations, n (%)	59 (100)	76 (100)
Remission: 0.0<=CDAI<=3.3	1 (1.7)	0 (0.0)
Low activity: 3.3<CDAI<=11.0	6 (10.2)	6 (7.6)
Moderate Activity: 11.0<CDAI<=26.0	34 (56.7)	42 (55.3)
High Activity: 26.0<CDAI<=86.0	18 (30.0)	30 (36.8)
Patient’s pain assessment, n	68	87
Mean (SD)	6.6 (2.1)	6.6 (1.9)
Median (P25; P75)	7.0 (5.0; 8.0)	7.0 (5.0; 8.0)